<DOC>
	<DOC>NCT01410448</DOC>
	<brief_summary>The purpose of this study is to evaluate whether delayed (i.e. 28 ± 4 days post-transplant) administration of everolimus after transplantation reduces the risk of wound healing complications in comparison with immediate administration in de novo renal transplant patients (proportion of patients without wound/surgical complications related to initial transplant surgery) between randomization and 3 months after transplantation</brief_summary>
	<brief_title>Everolimus in de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criteria: Patients who are willing and able to participate in the study and who provide written informed consent before performing any study related procedure; Men or women ≥18 years at transplant; Recipients of 1st or 2nd single kidney transplant from deceased donor or living unrelated/related donor &gt; 14 years; Exclusion criteria: Patients who are recipients of multiple organs transplant, including two kidneys; Historical or current peak PRA &gt; 50%. Patients with already existing antibodies against the donor; Thrombocytopenia (platelets &lt; 75,000/mm³), absolute neutrophil count &lt;1,500/mm³, leucopenia (leucocytes &lt; 2,500/mm³) or hemoglobin &lt; 7 g/dL; Body mass index (BMI) &gt; 30 Kg/m2; Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>safety</keyword>
</DOC>